These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 27487572)
1. Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. Matsuo M; Iwanaga M; Kondo H; Soda M; Jo T; Horio K; Takasaki Y; Kawaguchi Y; Tsushima H; Imaizumi Y; Imanishi D; Taguchi J; Sawayama Y; Hata T; Miyazaki Y Cancer Sci; 2016 Oct; 107(10):1484-1491. PubMed ID: 27487572 [TBL] [Abstract][Full Text] [Related]
2. Chromosomal analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Horai M; Satoh S; Matsuo M; Iwanaga M; Horio K; Jo T; Takasaki Y; Kawaguchi Y; Tsushima H; Yoshida S; Taguchi M; Itonaga H; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Moriuchi Y; Haase D; Yoshiura KI; Miyazaki Y Br J Haematol; 2018 Feb; 180(3):381-390. PubMed ID: 29265181 [TBL] [Abstract][Full Text] [Related]
3. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy. Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079 [TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967 [TBL] [Abstract][Full Text] [Related]
5. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience. Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870 [TBL] [Abstract][Full Text] [Related]
6. Impact of Nagasaki atomic bomb exposure on myelodysplastic syndrome patients who are treated with azacitidine. Jo T; Horio K; Shigematsu K Anticancer Res; 2015 May; 35(5):2929-33. PubMed ID: 25964578 [TBL] [Abstract][Full Text] [Related]
7. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories. Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720 [TBL] [Abstract][Full Text] [Related]
8. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988 [TBL] [Abstract][Full Text] [Related]
9. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. Iwanaga M; Hsu WL; Soda M; Takasaki Y; Tawara M; Joh T; Amenomori T; Yamamura M; Yoshida Y; Koba T; Miyazaki Y; Matsuo T; Preston DL; Suyama A; Kodama K; Tomonaga M J Clin Oncol; 2011 Feb; 29(4):428-34. PubMed ID: 21149671 [TBL] [Abstract][Full Text] [Related]
10. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415 [TBL] [Abstract][Full Text] [Related]
11. Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Taguchi M; Mishima H; Shiozawa Y; Hayashida C; Kinoshita A; Nannya Y; Makishima H; Horai M; Matsuo M; Sato S; Itonaga H; Kato T; Taniguchi H; Imanishi D; Imaizumi Y; Hata T; Takenaka M; Moriuchi Y; Shiraishi Y; Miyano S; Ogawa S; Yoshiura KI; Miyazaki Y Haematologica; 2020; 105(2):358-365. PubMed ID: 31101757 [TBL] [Abstract][Full Text] [Related]
12. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799 [TBL] [Abstract][Full Text] [Related]
13. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769 [TBL] [Abstract][Full Text] [Related]
14. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234 [TBL] [Abstract][Full Text] [Related]
15. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839 [TBL] [Abstract][Full Text] [Related]
16. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes]. Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954 [TBL] [Abstract][Full Text] [Related]